Specialty Overview

Best Hospitals for Sickle Cell Disease Treatment in Mumbai, India

17 hematology hospitals in our India network are listed in Mumbai, accredited by JCI, NABH, NABL, ISO 9001, with 6,503 beds combined.

17
Hospitals Listed
1
City
4.6
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the hematology hospitals in our directory offering Sickle Cell Disease Treatment in Mumbai, India, including Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai and others. Each listing links through to the hospital's full profile page.

Ask us about sickle cell disease treatment in Mumbai, India

Share a few details and our care coordination team will get back to you with next steps.

Top Hospitals for Sickle Cell Disease Treatment in Mumbai, India

🇮🇳 Nanavati Super Specialty Hospital

Mumbai, India 5 (12 reviews) 350 beds
Why consider this hospital?
5/5 rating from 12 reviews350 beds
Specialties & Accreditation
OncologyCardiac SurgeryNeurosciencesTransplantBariatrics
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Nanavati Super Specialty Hospital's care team in Mumbai, India, from initial consultation through recovery. Nanavati Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

5/5
Rating
1950
Established
350
Beds
Mumbai, India
Location
Kokilaben Dhirubhai Ambani Hospital

🇮🇳 Kokilaben Dhirubhai Ambani Hospital

Mumbai, India 4.8 (1800 reviews) 750 beds
Why consider this hospital?
4.8/5 rating from 1800 reviews750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Kokilaben Dhirubhai Ambani Hospital's care team in Mumbai, India, from initial consultation through recovery. Kokilaben Dhirubhai Ambani Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.8/5
Rating
2009
Established
750
Beds
Mumbai, India
Location
Tata Memorial Hospital

🇮🇳 Tata Memorial Hospital

Mumbai, India 4.8 (2500 reviews) 629 beds
Why consider this hospital?
4.8/5 rating from 2500 reviews629 beds
Specialties & Accreditation
OncologyCancer Center
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Tata Memorial Hospital's care team in Mumbai, India, from initial consultation through recovery. Tata Memorial Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.8/5
Rating
1941
Established
629
Beds
Mumbai, India
Location
Apollo Hospitals, Navi Mumbai

🇮🇳 Apollo Hospitals, Navi Mumbai

Mumbai, India 4.8 (512 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 512 reviews500 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Apollo Hospitals, Navi Mumbai's care team in Mumbai, India, from initial consultation through recovery. Apollo Hospitals, Navi Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.8/5
Rating
2016
Established
500
Beds
Mumbai, India
Location
Gleneagles Hospital, Mumbai

🇮🇳 Gleneagles Hospital, Mumbai

Mumbai, India 4.8 (615 reviews) 638 beds
Why consider this hospital?
4.8/5 rating from 615 reviews638 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Gleneagles Hospital, Mumbai's care team in Mumbai, India, from initial consultation through recovery. Gleneagles Hospital, Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.8/5
Rating
2008
Established
638
Beds
Mumbai, India
Location
Lilavati Hospital And Research Centre

🇮🇳 Lilavati Hospital And Research Centre

Mumbai, India 4.8 (724 reviews) 326 beds
Why consider this hospital?
4.8/5 rating from 724 reviews326 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
JCIJoint Commission International accreditationNABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Lilavati Hospital And Research Centre's care team in Mumbai, India, from initial consultation through recovery. Lilavati Hospital And Research Centre, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.8/5
Rating
1997
Established
326
Beds
Mumbai, India
Location
Jaslok Hospital

🇮🇳 Jaslok Hospital

Mumbai, India 4.6 (129 reviews) 350 beds
Why consider this hospital?
4.6/5 rating from 129 reviews350 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesOncologyOrthopedicsTransplant
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationNABLNational Accreditation Board for Testing and Calibration Laboratories accreditation

Patients considering sickle cell disease treatment can be cared for by Jaslok Hospital's care team in Mumbai, India, from initial consultation through recovery. Jaslok Hospital, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.6/5
Rating
1973
Established
350
Beds
Mumbai, India
Location
Gleneagles Global Hospitals (Global Hospitals)

🇮🇳 Gleneagles Global Hospitals (Global Hospitals)

Parel, Mumbai, India 4.6 (183 reviews) 450 beds
Why consider this hospital?
4.6/5 rating from 183 reviews450 beds
Specialties & Accreditation
Liver TransplantCardiac SurgeryOrthopedicsOncologyNeurosciences
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditationJCIJoint Commission International accreditation

Patients considering sickle cell disease treatment can be cared for by Gleneagles Global Hospitals (Global Hospitals)'s care team in Parel, Mumbai, India, from initial consultation through recovery. Gleneagles Global Hospitals (Global Hospitals), accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.6/5
Rating
1996
Established
450
Beds
Parel, Mumbai, India
Location
Medicover Hospital, Navi Mumbai

🇮🇳 Medicover Hospital, Navi Mumbai

Navi Mumbai, India 4.6 (143 reviews) 310 beds
Why consider this hospital?
4.6/5 rating from 143 reviews310 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyOrthopedicsNeurologyGastroenterology
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by Medicover Hospital, Navi Mumbai's care team in Navi Mumbai, India, from initial consultation through recovery. Medicover Hospital, Navi Mumbai, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.6/5
Rating
2023
Established
310
Beds
Navi Mumbai, India
Location
KIMS Hospitals, Thane

🇮🇳 KIMS Hospitals, Thane

Mumbai, India 4.6 (58 reviews) 300 beds
Why consider this hospital?
4.6/5 rating from 58 reviews300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
NABHNational Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering sickle cell disease treatment can be cared for by KIMS Hospitals, Thane's care team in Mumbai, India, from initial consultation through recovery. KIMS Hospitals, Thane, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing sickle cell disease treatment.

4.6/5
Rating
2025
Established
300
Beds
Mumbai, India
Location

Top Hematology Doctors in Mumbai, India

Image not available Featured

Dr. Muralidaran C

MBBS, MD, DM (Clinical Hematology)
Consultant Hematologist & Bone Marrow Transplant Physician · Specialty: Hematologist & BMT Specialist
Wockhardt Hospital Mumbai, India9+ Years experience
Why consider this doctor?
  • 9+ years of experience in Hematologist & BMT Specialist
  • Consultant Hematologist & Bone Marrow Transplant Physician, Wockhardt Hospital, Mumbai — Present
  • Superspecialty Medical Officer, MCGM–CTC PHO BMT Centre, Mumbai
Expertise & Procedures
  • Bone Marrow Aspiration and Biopsy
  • Autologous Stem Cell Transplantation (ASCT)
  • Allogeneic Bone Marrow Transplantation
  • Haploidentical BMT with Haploidentical Donors
  • Lymph Node Fine Needle Aspiration Cytology (FNAC)
View all procedures →
Hematologist & BMT Specialist Experience: 9+ YearsHospital Affiliation: Wockhardt HospitalHospital accreditation: NABH, NABL
Image not available

Dr. Vipin Khandelwal

MBBS, MD (Paediatrics), DM (Paediatric Oncology), PDF (Paediatric Haematology & BMT)
Consultant — Paediatric Haematology, Oncology & Bone Marrow Transplantation · Specialty: Paediatric Haematologist & BMT Specialist
Apollo Hospitals Navi Mumbai, India12+ Years experience
Why consider this doctor?
  • 12+ years of experience in Paediatric Haematologist & BMT Specialist
  • Consultant — Paediatric Haematology, Oncology & Bone Marrow Transplantation, Apollo Hospitals, Navi Mumbai
  • Advanced training in Paediatric Haematology and Bone Marrow Transplantation
Expertise & Procedures
  • Paediatric Bone Marrow Transplantation (BMT)
  • Haploidentical Stem Cell Transplantation
  • Matched Sibling Donor Transplant
  • Matched Unrelated Donor Transplant
  • Autologous Stem Cell Transplantation
View all procedures →
Paediatric Haematologist & BMT Specialist Experience: 12+ YearsHospital Affiliation: Apollo HospitalsHospital accreditation: JCI, NABH
Our Methodology

How we selected these hospitals

A hospital appears on this page when Hematology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Sickle Cell Disease Treatment in Mumbai, India?

Choosing the right hospital for sickle cell disease treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include hematology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Sickle Cell Disease Treatment

Sickle Cell Disease (SCD) is a severe inherited hemoglobinopathy requiring lifelong, multidisciplinary management — from hydroxyurea therapy and chronic transfusion programs to potentially curative allogeneic Bone Marrow Transplantation (BMT).

BMT: 30–45 days in-hospital (conditioning + engraftment + early monitoring); Hydroxyurea/Crisis Care: 5–10 days per acute admission
Hospital Stay
BMT: 3–6 months in-country (immune reconstitution monitoring required before international travel); Hydroxyurea initiation / Crisis Care only: 2–4 weeks
Total Stay in Country (Fit-to-Fly)
BMT (matched sibling donor, pediatric): 85–92% event-free survival; Hydroxyurea response rate: 70–80% reduction in vaso-occlusive crisis frequency
Success Rate

Clinical Overview

  • Sickle Cell Disease is caused by a point mutation in the HBB gene (Glu6Val), resulting in the production of hemoglobin S (HbS).
  • Under conditions of hypoxia, dehydration, or acidosis, HbS polymerizes, distorting red blood cells into a rigid, sickle-shaped morphology.
  • These cells obstruct microvasculature, triggering vaso-occlusive crises (VOC), acute chest syndrome (ACS), splenic sequestration, and chronic end-organ damage affecting the kidneys, lungs, brain, liver, and retina.
Full details →

Who is a Candidate?

  • **Eligible for Allogeneic BMT (Curative Intent):**
  • Children and young adults (ideally under 16 years; adult BMT up to age 40–45 at experienced centers) with severe SCD (HbSS or HbSβ⁰-thalassemia genotype)
  • History of ≥2 acute chest syndrome episodes, ≥1 clinical stroke or silent cerebral infarct on MRI, recurrent severe VOC (≥3 hospitalizations/year despite hydroxyurea), chronic transfusion dependency, or progressive sickle nephropathy
  • Availability of an HLA-matched sibling donor (10/10 match preferred; haploidentical protocols expanding eligibility)
  • +24 more

Treatment Options & Approaches

  • **1.
  • Hydroxyurea (Hydroxycarbamide) Therapy — Disease Modification**

Recovery

  • **Phase 1 — Remote Pre-Assessment (Weeks 1–3, from home country)**

Risks to be aware of

  • Patients and families must be counseled on the following procedure-specific risks before committing to any SCD treatment pathway.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides a fully integrated medical travel management service covering every non-clinical dimension of the patient's journey to India or the UAE.

Common questions about Sickle Cell Disease Treatment

What is the cost of Sickle Cell Disease Treatment — Hydroxyurea, BMT & Crisis Care — in India vs. the UAE?
The cost varies significantly based on the treatment pathway selected. For Allogeneic Bone Marrow Transplantation (BMT), the total cost in India typically ranges from USD 18,000 to USD 40,000, covering pre-transplant workup, conditioning chemotherapy, stem cell infusion, a 30–45 day hospital stay, early post-transplant monitoring, and standard medications including GvHD prophylaxis agents (tacrolimus, methotrexate, ATG). In the UAE (Dubai/Abu Dhabi), an equivalent BMT program costs approximately USD 45,000 to USD 90,000 at JCI/DHA-accredited centers such as Cleveland Clinic Abu Dhabi or King's College Hospital Dubai. For hydroxyurea initiation and medical management without BMT, costs in India range from USD 2,000–6,000 per treatment episode, versus USD 5,000–12,000 in the UAE. Acute vaso-occlusive crisis management (hospitalization, IV opioid analgesia, exchange transfusion if required) costs approximately USD 1,500–4,000 per episode in India and USD 4,000–9,000 per episode in the UAE. India offers JCI and NABH-accredited transplant centers with outcome data equivalent to international benchmarks at 50–60% lower cost than the UAE. The UAE offers premium facilities, luxury patient rooms, and seamless access for patients flying from the Middle East and East Africa. Both destinations include BMT-specific inclusions: HLA typing, pharmacokinetically dosed conditioning, engraftment monitoring, and chimerism analysis. Costs are indicative; GAF Healthcare provides a personalized cost estimate within 48 hours of receiving the patient's medical records.
How long do I need to stay in India or the UAE before I am fit to fly home after Sickle Cell Disease treatment?
The required in-country stay depends entirely on the treatment pathway. For patients undergoing Allogeneic Bone Marrow Transplantation (BMT), the minimum safe in-country stay is 90 days, and most transplant protocols recommend 120–180 days (4–6 months) before international air travel is approved. This extended stay is clinically essential: the first 100 days post-transplant are the highest-risk period for graft failure, severe acute GvHD, and life-threatening opportunistic infections (CMV, invasive aspergillosis, Pneumocystis pneumonia). The treating hematologist will clear the patient for international travel only when: (1) neutrophil and platelet engraftment is stable and sustained, (2) donor chimerism is ≥95% on two consecutive assessments, (3) immunosuppression is being tapered without GvHD flare, (4) no active infection is present, and (5) the patient can access equivalent emergency hematology/transplant care within their home country. For patients treated only with hydroxyurea initiation or acute crisis management without BMT, the required stay is much shorter — typically 2–4 weeks. This allows time for the treating team to confirm hydroxyurea dose tolerability (ANC and platelet response at Week 2–3), complete post-crisis clinical stability assessment, and prepare a detailed outpatient management plan for the home-country physician. GAF Healthcare coordinates a fit-to-fly certification letter from the treating physician and arranges medical escort services for BMT patients requiring in-flight medical supervision on the return journey if residual immunosuppression or clinical fragility warrants it.
What is the success rate of Sickle Cell Disease treatment — particularly BMT — in India and the UAE?
Success rates for Sickle Cell Disease treatment differ significantly by treatment modality and must be interpreted carefully. For Allogeneic BMT using a matched sibling donor (MSD) in pediatric patients (under 16 years), leading Indian transplant centers (Apollo, Tata Memorial, Narayana Health) and UAE centers (Cleveland Clinic Abu Dhabi) report event-free survival (EFS) rates of 85–92% at 5 years, with overall survival (OS) of 90–95%. These outcomes are consistent with published data from the European Group for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). In adult SCD patients (16–40 years), EFS is slightly lower at 75–85% with MSD BMT, due to higher rates of GvHD and treatment-related complications. Haploidentical (half-matched donor) BMT, now performed at advanced centers in India and the UAE using post-transplant cyclophosphamide protocols, reports EFS of 60–75% — a significant improvement in patients who lack a fully matched donor. For hydroxyurea therapy, clinical response is defined as a ≥50% reduction in annualized vaso-occlusive crisis rate and/or ACS episodes, achieved in approximately 70–80% of patients who reach maximum tolerated dose and maintain compliance. Hemoglobin F levels rise from a baseline of 5–8% to 15–25% in responders, substantially reducing HbS polymerization and disease severity. For emerging gene therapy approaches (betibeglogene spartivec, exagamglogene autotemcel), early trial data show transfusion independence in >90% of treated patients at 2-year follow-up, though long-term durability data (>5 years) are still maturing. GAF Healthcare only partners with centers that publish and can demonstrate transparent outcome data, including transplant-related mortality rates, GvHD incidence, and engraftment success rates, so patients can make fully informed decisions.

How GAF Healthcare Assists in Choosing the Best Hospital for Sickle Cell Disease Treatment in Mumbai, India

Discover the Top Hospitals for Sickle Cell Disease Treatment in Mumbai, India

This page lists 17 accredited hematology hospitals in Mumbai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Patient Success Story

Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions

Frequently asked questions about sickle cell disease treatment in Mumbai, India

How many hematology hospitals are listed in Mumbai, India?
17 hospitals in our Mumbai, India directory are currently listed for hematology including Sickle Cell Disease Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Hematology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there hematology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO 9001 — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for sickle cell disease treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about sickle cell disease treatment in Mumbai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for sickle cell disease treatment in Mumbai, India.

Contact us to report an inaccuracy on this page.